Expertise in
18
conditions

Dr. David J. Sher

Radiation Oncology
Office
2280 Inwood Rd, 
Dallas, TX 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
18
conditions
Office
2280 Inwood Rd, 
Dallas, TX 

Overview

David Sher is a Radiation Oncologist practicing medicine in Dallas, Texas.

Dr. Sher is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Throat Cancer, Laryngeal Cancer, Head and Neck Squamous Cell Carcinoma (HNSCC), Teratocarcinosarcoma, and Gastrostomy.

He is actively involved in clinical research, co-authoring 223 peer reviewed articles and participating in 7 clinical trials.

Specialties

Radiation Oncology

Licenses

Radiology in MA

Hospital Affiliations

Parkland Health & Hospital System
UT Of Texas Southwestern University Hospital - William P. Clements Jr.

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Baylor Scott & White Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

Office
2280 Inwood Rd, Dallas, TX 75235

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Phase II Randomized Trial of Radiotherapy With or Without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) With TP53 Sequencing
Phase II Randomized Trial of Radiotherapy With or Without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) With TP53 Sequencing
Enrollment Status: Recruiting
Publish Date: August 19, 2026
Intervention Type: Drug, Other, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck
Enrollment Status: Suspended
Publish Date: September 01, 2026
Intervention Type: Procedure, Drug, Other, Radiation, Biological
Study Drugs: Atezolizumab, Cetuximab, Cisplatin, Docetaxel
Study Phase: Phase 2/Phase 3
Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)
Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure, Drug, Radiation
Study Drugs: Cisplatin, Fluorouracil, Gemcitabine Hydrochloride, Paclitaxel
Study Phase: Phase 2/Phase 3
A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC
A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPSCC
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Procedure, Drug, Biological, Radiation, Other
Study Drugs: Cisplatin, Nivolumab
Study Phase: Phase 3
A Randomized Phase II/Phase III Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors
A Randomized Phase II/Phase III Study of Adjuvant Concurrent Radiation and Chemotherapy Versus Radiation Alone in Resected High-Risk Malignant Salivary Gland Tumors
Enrollment Status: Active_not_recruiting
Publish Date: May 27, 2026
Intervention Type: Drug, Radiation
Study Drug: Cisplatin
Study Phase: Phase 2
KEYSTROKE: A Randomized Phase II Study of Pembrolizumab (KEYTRUDA®) Plus Stereotactic Re-irradiation Versus SBRT Alone for Locoregionally Recurrent or Second Primary Head and Neck Carcinoma
KEYSTROKE: A Randomized Phase II Study of Pembrolizumab (KEYTRUDA®) Plus Stereotactic Re-irradiation Versus SBRT Alone for Locoregionally Recurrent or Second Primary Head and Neck Carcinoma
Enrollment Status: Active_not_recruiting
Publish Date: January 20, 2026
Intervention Type: Radiation, Drug
Study Drug: Pembrolizumab
Study Phase: Phase 2
A Phase 2a Randomized, Parallel Group, Open Label, Multicenter Study to Assess the Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for the Treatment of Locally Advanced Squamous Cell Carcinoma of the Oral Cavity or Oropharynx
A Phase 2a Randomized, Parallel Group, Open Label, Multicenter Study to Assess the Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for the Treatment of Locally Advanced Squamous Cell Carcinoma of the Oral Cavity or Oropharynx
Enrollment Status: Completed
Publish Date: November 04, 2024
Intervention Type: Drug, Radiation
Study Phase: Phase 2
View 6 Less Clinical Trials

223 Total Publications

Notably Off Key: Questioning the Clinical Benefit of Perioperative Immunotherapy for Resectable Head and Neck Squamous Cell Carcinoma After KEYNOTE-689.
Notably Off Key: Questioning the Clinical Benefit of Perioperative Immunotherapy for Resectable Head and Neck Squamous Cell Carcinoma After KEYNOTE-689.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: April 22, 2026
Similar Doctors
Expertise in
9
conditions
Dr. Kevin V. Albuquerque
Radiation Oncology
Expertise in
9
conditions
Dr. Kevin V. Albuquerque
Radiation Oncology
Referral may be required

University Of Texas Southwestern Medical Center

5323 Harry Hines Blvd, 
Dallas, TX 
 (0.4 miles away)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Kevin Albuquerque is a Radiation Oncologist practicing medicine in Dallas, Texas. Dr. Albuquerque is highly rated in 9 conditions, according to our data. His clinical expertise encompasses Cervical Cancer, Endometrial Cancer, Vulvar Cancer, Vaginal Cancer, and Lymphadenectomy.

Expertise in
27
conditions
Dr. Tu D. Dan
Radiation Oncology
Expertise in
27
conditions
Dr. Tu D. Dan
Radiation Oncology
Referral may be required

Office

2280 Inwood Rd, 
Dallas, TX 
 (0.1 miles away)
214-645-8525
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Tu Dan is a Radiation Oncologist practicing medicine in Dallas, Texas. Dr. Dan is highly rated in 27 conditions, according to our data. His clinical expertise encompasses Brain Tumor, Glioma, Metastatic Brain Tumor, Posterior Fossa Tumor, and Gamma Knife Radiosurgery.

Expertise in
24
conditions
Dr. Shahed N. Badiyan
Radiation Oncology
Expertise in
24
conditions
Dr. Shahed N. Badiyan
Radiation Oncology
Referral may be required

Office

2280 Inwood Rd, 
Dallas, TX 
 (0.1 miles away)
214-645-8525
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Shahed Badiyan is a Radiation Oncologist practicing medicine in Dallas, Texas. Dr. Badiyan is highly rated in 24 conditions, according to our data. His clinical expertise encompasses Lung Cancer, Pleuropulmonary Blastoma, Posterior Fossa Tumor, and Primitive Neuroectodermal Tumor (PNET).

Frequently Asked Questions about Dr. David J. Sher

How do I make an appointment with Dr. David J. Sher?

You can book an appointment with Dr. David J. Sher by calling their office at 214-645-8525. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. David J. Sher a top-rated expert for Throat Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. David J. Sher is classified as an Elite expert for Throat Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. David J. Sher specialize in?

While Dr. David J. Sher is a Radiation Oncology, they have specific expertise in Throat Cancer, Laryngeal Cancer, and Head and Neck Squamous Cell Carcinoma (HNSCC). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Radiation Oncology.

Does Dr. David J. Sher participate in research or clinical trials?

Yes. Dr. David J. Sher has published 223 articles and abstracts on conditions like Throat Cancer. You can view a list of Dr. David J. Sher's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. David J. Sher accept my insurance?

Dr. David J. Sher accepts most major insurance plans, including Aetna and Baylor Scott & White Health. We recommend calling the office directly at 214-645-8525 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Sher's expertise for a condition
ConditionClose
View All 12 Advanced Conditions
View All 42 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile